Attached files
| file | filename |
|---|---|
| 8-K - 8-K - AGILENT TECHNOLOGIES, INC. | form8-kxq217pressrelease.htm |
Exhibit 99.1
INVESTOR CONTACT:
Alicia Rodriguez
+1 408 345 8948
alicia_rodriguez@agilent.com
EDITORIAL CONTACT:
Stefanie Notaney
+1 408 345 8955
stefanie.notaney@agilent.com
Agilent Technologies Reports Second-Quarter
Fiscal Year 2017 Financial Results
Strong Second Quarter, Raises Full-Year Guidance
Highlights:
• | GAAP net income of $164 million, or $0.50 per share |
• | Non-GAAP net income of $187 million, or $0.58 per share(1), $0.10 above midpoint guidance of $0.48 per share |
• | Revenue of $1.10 billion, representing growth of 8 percent (core revenue growth of 9 percent(2) versus midpoint guidance of 3.5 percent) |
• | Third-quarter fiscal year revenue guidance of $1.06 billion to $1.08 billion, and non-GAAP earnings guidance of $0.49 to $0.51 per share(3). |
• | Increasing fiscal year 2017 core revenue growth guidance from a midpoint of 4.5 percent to 5.0 percent(2). Increasing non-GAAP earnings guidance from a midpoint of $2.13 to $2.18 per share(3). |
SANTA CLARA, Calif., May 22, 2017 -- Agilent Technologies Inc. (NYSE: A) today reported revenue of $1.10 billion, up 8 percent year over year (up 9 percent on a core basis(2)) for the second fiscal quarter ended April 30, 2017.
Second-quarter GAAP net income was $164 million, or $0.50 per share. Last year’s second-quarter GAAP net income was $91 million, or $0.28 per share.
During the second quarter, Agilent had intangible amortization of $31 million, acquisition and integration costs of $7 million, and $2 million in other costs. Excluding
1
these items and a tax benefit of $17 million, Agilent reported second-quarter non-GAAP net income of $187 million, or $0.58 per share(1).
“The Agilent team delivered another excellent quarter,” said Mike McMullen, Agilent President and CEO. “Both revenue and earnings per share exceeded the high range of guidance. We saw a strong pick up in the Chemical and Energy business after modest gains last quarter, and strong growth in Pharma and Europe also contributed to the upside.”
“We continue to deliver on our long-term focus of driving above market growth, expanding operating margins, and deploying capital in a balanced manner,” he added. “Looking ahead, we are confident in our company’s prospects, and we are raising our full-year core revenue growth and earnings expectations.”
Second-quarter revenue of $523 million from Agilent’s Life Sciences and Applied Markets Group (LSAG) grew 6 percent year over year (up 6 percent on a core basis(2)), with double-digit growth in chemical and energy, pharma and environmental markets. LSAG’s operating margin for the quarter was 21.1 percent.
Second-quarter revenue of $378 million from Agilent CrossLab Group (ACG) grew 9 percent year over year (up 10 percent on a core basis(2)). Both services and consumables continued to see solid growth across all geographies. ACG’s operating margin for the quarter was 21.6 percent.
Second-quarter revenue of $201 million from Agilent’s Diagnostics and Genomics Group (DGG) grew 13 percent year over year (up 13 percent on a core basis(2)) led by pharma and diagnostic and clinical end-markets. DGG’s operating margin for the quarter was 24.2 percent.
Agilent expects third-quarter 2017 revenue in the range of $1.06 billion to $1.08 billion. Third-quarter non-GAAP earnings are expected to be in the range of $0.49 to $0.51 per share(3).
For fiscal year 2017, Agilent expects revenue of $4.36 billion to $4.38 billion and non-GAAP earnings of $2.15 to $2.21 per share(3). The guidance is based on April 28, 2017 currency exchange rates.
About Agilent Technologies
Agilent Technologies, Inc. (NYSE: A), a global leader in life sciences, diagnostics and applied chemical markets, is the premier laboratory partner for a better world. Agilent works with customers in more than 100 countries, providing instruments, software,
2
services and consumables for the entire laboratory workflow. Agilent generated revenue of $4.20 billion in fiscal 2016. The company employs about 13,000 people worldwide. Information about Agilent is available at www.agilent.com.
Agilent’s management will present more details about its second-quarter FY2017 financial results on a conference call with investors today at 1:30 p.m. PT. This event will be webcast live in listen-only mode. Listeners may log on at www.investor.agilent.com and select “Q2 2017 Agilent Technologies Inc. Earnings Conference Call” in the “News & Events Calendar of Events” section. The webcast will remain available on the company’s website for 90 days.
Additional information regarding financial results can be found at www.investor.agilent.com by selecting “Financial Results” in the “Financial Information” section.
A telephone replay of the conference call will be available at approximately 4:30 p.m. PST today through May 29, 2017 by dialing +1 800-585-8367 (or +1 404-537-3406 from outside the United States) and entering pass code 8574751.
Forward-Looking Statements
This news release contains forward-looking statements as defined in the Securities Exchange Act of 1934 and is subject to the safe harbors created therein. The forward-looking statements contained herein include, but are not limited to, information regarding Agilent’s future revenue, earnings and profitability; planned new products; market trends; the future demand for the company’s products and services; customer expectations; and revenue and non-GAAP earnings guidance for the third quarter and full fiscal year 2017. These forward-looking statements involve risks and uncertainties that could cause Agilent’s results to differ materially from management’s current expectations. Such risks and uncertainties include, but are not limited to, unforeseen changes in the strength of our customers’ businesses; unforeseen changes in the demand for current and new products,
3
technologies, and services; unforeseen changes in the currency markets; customer purchasing decisions and timing, and the risk that we are not able to realize the savings expected from integration and restructuring activities.
In addition, other risks that Agilent faces in running its operations include the ability to execute successfully through business cycles; the ability to meet and achieve the benefits of its cost-reduction goals and otherwise successfully adapt its cost structures to continuing changes in business conditions; ongoing competitive, pricing and gross-margin pressures; the risk that our cost-cutting initiatives will impair our ability to develop products and remain competitive and to operate effectively; the impact of geopolitical uncertainties and global economic conditions on our operations, our markets and our ability to conduct business; the ability to improve asset performance to adapt to changes in demand; the ability of our supply chain to adapt to changes in demand; the ability to successfully introduce new products at the right time, price and mix; the ability of Agilent to successfully integrate recent acquisitions; the ability of Agilent to successfully comply with certain complex regulations; and other risks detailed in Agilent’s filings with the Securities and Exchange Commission, including our quarterly report on Form 10-Q for the quarter ended Jan. 31, 2017. Forward-looking statements are based on the beliefs and assumptions of Agilent’s management and on currently available information. Agilent undertakes no responsibility to publicly update or revise any forward-looking statement.
# # #
(1) Non-GAAP net income and non-GAAP earnings per share primarily excludes the impacts of acquisition and integration costs, transformation initiatives, business exit and divestiture costs, non-cash intangibles amortization, and pension settlement and curtailment gains. We also exclude any tax benefits that are not directly related to ongoing operations and which are either isolated or is not expected to occur again with any regularity or predictability. A reconciliation between non-GAAP net income and GAAP net
4
income is set forth on page 6 of the attached tables along with additional information regarding the use of this non-GAAP measure.
(2) Core revenue growth excludes the impact of currency, the NMR business and acquisitions and divestitures within the past 12 months. Core revenue is a non-GAAP measure. A reconciliation between Q2 FY17 GAAP revenue and core revenue is set forth on page 8 of the attached tables along with additional information regarding the use of this non-GAAP measure. Core revenue growth as projected for full fiscal year 2017 excludes the impact of currency, the NMR business and acquisitions and divestitures within the past 12 months. Most of these exclude amounts that pertain to events that have not yet occurred and are not currently possible to estimate with a reasonable degree of accuracy and could differ materially. Therefore, no reconciliation to GAAP amounts has been provided.
(3) Non-GAAP earnings per share as projected for Q3 FY17 and full fiscal year 2017 excludes primarily the future impact of acquisition and integration costs, pension settlement gain, and non-cash intangibles amortization. We also exclude any tax benefits that are not directly related to ongoing operations and which are either isolated or is not expected to occur again with any regularity or predictability. Most of these excluded amounts that pertain to events that have not yet occurred and are not currently possible to estimate with a reasonable degree of accuracy and could differ materially. Therefore, no reconciliation to GAAP amounts has been provided. Future amortization of intangibles is expected to be approximately $30 million per quarter.
NOTE TO EDITORS: Further technology, corporate citizenship and executive news is available on the Agilent news site at www.agilent.com/go/news.
5
AGILENT TECHNOLOGIES, INC.
CONDENSED CONSOLIDATED STATEMENT OF OPERATIONS
(In millions, except per share amounts)
(Unaudited)
PRELIMINARY
Three Months Ended | ||||||||||
April 30, | Percent | |||||||||
2017 | 2016 | Inc/(Dec) | ||||||||
Net revenue | $ | 1,102 | $ | 1,019 | 8% | |||||
Costs and expenses: | ||||||||||
Cost of products and services | 510 | 489 | 4% | |||||||
Research and development | 84 | 81 | 4% | |||||||
Selling, general and administrative | 307 | 318 | (3)% | |||||||
Total costs and expenses | 901 | 888 | 1% | |||||||
Income from operations | 201 | 131 | 53% | |||||||
Interest income | 5 | 3 | 67% | |||||||
Interest expense | (20 | ) | (18 | ) | 11% | |||||
Other income (expense), net | 5 | 1 | — | |||||||
Income before taxes | 191 | 117 | 63% | |||||||
Provision for income taxes | 27 | 26 | 4% | |||||||
Net income | $ | 164 | $ | 91 | 80% | |||||
Net income per share: | ||||||||||
Basic | $ | 0.51 | $ | 0.28 | ||||||
Diluted | $ | 0.50 | $ | 0.28 | ||||||
Weighted average shares used in computing net income per share: | ||||||||||
Basic | 321 | 326 | ||||||||
Diluted | 325 | 328 | ||||||||
Cash dividends declared per common share | $ | 0.132 | $ | 0.115 | ||||||
The preliminary income statement is estimated based on our current information.
1
AGILENT TECHNOLOGIES, INC.
CONDENSED CONSOLIDATED STATEMENT OF OPERATIONS
(In millions, except per share amounts)
(Unaudited)
PRELIMINARY
Six Months Ended | ||||||||||
April 30, | Percent | |||||||||
2017 | 2016 | Inc/(Dec) | ||||||||
Net revenue | $ | 2,169 | $ | 2,047 | 6% | |||||
Costs and expenses: | ||||||||||
Cost of products and services | 1,003 | 980 | 2% | |||||||
Research and development | 163 | 159 | 3% | |||||||
Selling, general and administrative | 596 | 622 | (4)% | |||||||
Total costs and expenses | 1,762 | 1,761 | — | |||||||
Income from operations | 407 | 286 | 42% | |||||||
Interest income | 9 | 5 | 80% | |||||||
Interest expense | (40 | ) | (36 | ) | 11% | |||||
Other income (expense), net | 8 | 4 | 100% | |||||||
Income before taxes | 384 | 259 | 48% | |||||||
Provision for income taxes | 52 | 47 | 11% | |||||||
Net income | $ | 332 | $ | 212 | 57% | |||||
Net income per share: | ||||||||||
Basic | $ | 1.03 | $ | 0.65 | ||||||
Diluted | $ | 1.02 | $ | 0.64 | ||||||
Weighted average shares used in computing net income per share: | ||||||||||
Basic | 322 | 327 | ||||||||
Diluted | 325 | 330 | ||||||||
Cash dividends declared per common share | $ | 0.264 | $ | 0.230 | ||||||
The preliminary income statement is estimated based on our current information.
2
AGILENT TECHNOLOGIES, INC.
CONDENSED CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME
(In millions)
(Unaudited)
PRELIMINARY
Three Months Ended | Six Months Ended | ||||||||||||||||
April 30, | April 30, | ||||||||||||||||
2017 | 2016 | 2017 | 2016 | ||||||||||||||
Net Income | $ | 164 | $ | 91 | $ | 332 | $ | 212 | |||||||||
Other comprehensive income (loss), net of tax: | |||||||||||||||||
Unrealized loss on derivative instruments | (1 | ) | (9 | ) | — | (6 | ) | ||||||||||
Amounts reclassified into earnings related to derivative instruments | (1 | ) | — | (1 | ) | (1 | ) | ||||||||||
Foreign currency translation | 7 | 145 | 4 | 89 | |||||||||||||
Net defined benefit pension cost and post retirement plan costs: | |||||||||||||||||
Change in actuarial net loss | 9 | 6 | 26 | 21 | |||||||||||||
Change in net prior service benefit | (2 | ) | (3 | ) | (3 | ) | (11 | ) | |||||||||
Other comprehensive income | 12 | 139 | 26 | 92 | |||||||||||||
Total comprehensive income | $ | 176 | $ | 230 | $ | 358 | $ | 304 | |||||||||
The preliminary statement of comprehensive income is estimated based on our current information.
3
AGILENT TECHNOLOGIES, INC.
CONDENSED CONSOLIDATED BALANCE SHEET
(In millions, except par value and share amounts)
(Unaudited)
PRELIMINARY
April 30, 2017 | October 31, 2016 (a) | |||||||
ASSETS | ||||||||
Current assets: | ||||||||
Cash and cash equivalents | $ | 2,389 | $ | 2,289 | ||||
Accounts receivable, net | 677 | 631 | ||||||
Inventory | 548 | 533 | ||||||
Other current assets | 186 | 182 | ||||||
Total current assets | 3,800 | 3,635 | ||||||
Property, plant and equipment, net | 675 | 639 | ||||||
Goodwill | 2,568 | 2,517 | ||||||
Other intangible assets, net | 373 | 408 | ||||||
Long-term investments | 134 | 135 | ||||||
Other assets | 466 | 460 | ||||||
Total assets | $ | 8,016 | $ | 7,794 | ||||
LIABILITIES AND EQUITY | ||||||||
Current liabilities: | ||||||||
Accounts payable | $ | 265 | $ | 257 | ||||
Employee compensation and benefits | 241 | 235 | ||||||
Deferred revenue | 301 | 269 | ||||||
Short-term debt | 241 | — | ||||||
Other accrued liabilities | 139 | 184 | ||||||
Total current liabilities | 1,187 | 945 | ||||||
Long-term debt | 1,802 | 1,904 | ||||||
Retirement and post-retirement benefits | 317 | 360 | ||||||
Other long-term liabilities | 335 | 339 | ||||||
Total liabilities | 3,641 | 3,548 | ||||||
Total Equity: | ||||||||
Stockholders' equity: | ||||||||
Preferred stock; $0.01 par value; 125 million shares authorized; none issued and outstanding | — | — | ||||||
Common stock; $0.01 par value; 2 billion shares authorized; 321 million shares at April 30, 2017 and 614 million shares at October 31, 2016, issued | 3 | 6 | ||||||
Treasury stock at cost; zero shares at April 30, 2017 and 290 million shares at October 31, 2016 | — | (10,508 | ) | |||||
Additional paid-in-capital | 5,239 | 9,159 | ||||||
Retained earnings (accumulated deficit) | (393 | ) | 6,089 | |||||
Accumulated other comprehensive loss | (477 | ) | (503 | ) | ||||
Total stockholders' equity | 4,372 | 4,243 | ||||||
Non-controlling interest | 3 | 3 | ||||||
Total equity | 4,375 | 4,246 | ||||||
Total liabilities and equity | $ | 8,016 | $ | 7,794 | ||||
(a) Includes the impact of the adoption of ASU 2015-15.
The preliminary balance sheet is estimated based on our current information.
4
AGILENT TECHNOLOGIES, INC.
CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS
(In millions)
(Unaudited)
PRELIMINARY
Three Months Ended | Three Months Ended | Six Months Ended | Six Months Ended | ||||||||||||||
April 30, | April 30, | April 30, | April 30, | ||||||||||||||
2017 | 2016 | 2017 | 2016 | ||||||||||||||
Cash flows from operating activities: | |||||||||||||||||
Net income | $ | 164 | $ | 91 | $ | 332 | $ | 212 | |||||||||
Adjustments to reconcile net income to net cash provided by (used in) operating activities: | |||||||||||||||||
Depreciation and amortization | 54 | 64 | 109 | 130 | |||||||||||||
Share-based compensation | 15 | 13 | 35 | 36 | |||||||||||||
Excess and obsolete inventory related charges | 8 | 8 | 15 | 12 | |||||||||||||
Other non-cash expenses, net | — | 6 | 2 | 8 | |||||||||||||
Changes in assets and liabilities: | |||||||||||||||||
Accounts receivable | (17 | ) | 34 | (48 | ) | 19 | |||||||||||
Inventory | (3 | ) | — | (29 | ) | (13 | ) | ||||||||||
Accounts payable | (3 | ) | (35 | ) | 6 | (53 | ) | ||||||||||
Employee compensation and benefits | 50 | 34 | 7 | (13 | ) | ||||||||||||
Other assets and liabilities | (11 | ) | 39 | (56 | ) | 27 | |||||||||||
Net cash provided by operating activities (a) | 257 | 254 | 373 | 365 | |||||||||||||
Cash flows from investing activities: | |||||||||||||||||
Investments in property, plant and equipment | (43 | ) | (25 | ) | (75 | ) | (63 | ) | |||||||||
Proceeds from divestitures | — | — | 1 | — | |||||||||||||
Proceeds from sale of investment securities | — | — | — | 1 | |||||||||||||
Payment to acquire cost method investment | — | (80 | ) | — | (80 | ) | |||||||||||
Loan to equity method investment | — | (3 | ) | — | (3 | ) | |||||||||||
Change in restricted cash and cash equivalents, net | — | — | — | 245 | |||||||||||||
Payment in exchange for convertible note | — | — | — | (1 | ) | ||||||||||||
Acquisition of businesses and intangible assets, net of cash acquired | — | — | (70 | ) | (235 | ) | |||||||||||
Net cash used in investing activities | (43 | ) | (108 | ) | (144 | ) | (136 | ) | |||||||||
Cash flows from financing activities: | |||||||||||||||||
Issuance of common stock under employee stock plans | 8 | 8 | 26 | 32 | |||||||||||||
Payment of taxes related to net share settlement of equity awards | (1 | ) | — | (13 | ) | (5 | ) | ||||||||||
Payment of dividends | (43 | ) | (37 | ) | (85 | ) | (75 | ) | |||||||||
Proceeds from revolving credit facility | 97 | 155 | 228 | 255 | |||||||||||||
Repayment of revolving credit facility | (45 | ) | — | (87 | ) | (20 | ) | ||||||||||
Treasury stock repurchases | (83 | ) | (94 | ) | (194 | ) | (294 | ) | |||||||||
Net cash provided by (used in) financing activities | (67 | ) | 32 | (125 | ) | (107 | ) | ||||||||||
Effect of exchange rate movements | 1 | 30 | (4 | ) | 14 | ||||||||||||
Net increase in cash and cash equivalents | 148 | 208 | 100 | 136 | |||||||||||||
Cash and cash equivalents at beginning of period | 2,241 | 1,931 | 2,289 | 2,003 | |||||||||||||
Cash and cash equivalents at end of period | $ | 2,389 | $ | 2,139 | $ | 2,389 | $ | 2,139 | |||||||||
(a) Cash payments included in operating activities: | |||||||||||||||||
Severance payments | $ | 2 | $ | 1 | $ | 3 | $ | 3 | |||||||||
Income tax payments (refunds), net | $ | 14 | $ | (16 | ) | $ | 41 | $ | 21 | ||||||||
Interest payments | $ | 11 | $ | 8 | $ | 40 | $ | 37 | |||||||||
The preliminary cash flow is estimated based on our current information.
5
AGILENT TECHNOLOGIES, INC.
NON-GAAP NET INCOME AND DILUTED EPS RECONCILIATIONS
(In millions, except per share amounts)
(Unaudited)
PRELIMINARY
Three Months Ended | Six Months Ended | ||||||||||||||||||||||||||||||||
April 30, | April 30, | ||||||||||||||||||||||||||||||||
2017 | Diluted EPS | 2016 | Diluted EPS | 2017 | Diluted EPS | 2016 | Diluted EPS | ||||||||||||||||||||||||||
GAAP Net income | $ | 164 | $ | 0.50 | $ | 91 | $ | 0.28 | $ | 332 | $ | 1.02 | $ | 212 | $ | 0.64 | |||||||||||||||||
Non-GAAP adjustments: | |||||||||||||||||||||||||||||||||
Intangible amortization | 31 | 0.10 | 40 | 0.12 | 62 | 0.19 | 83 | 0.25 | |||||||||||||||||||||||||
Business exit and divestiture costs | — | — | 1 | — | — | — | 5 | 0.02 | |||||||||||||||||||||||||
Transformational initiatives | — | — | 10 | 0.03 | 2 | 0.01 | 21 | 0.06 | |||||||||||||||||||||||||
Acquisition and integration costs | 7 | 0.02 | 12 | 0.04 | 23 | 0.07 | 17 | 0.05 | |||||||||||||||||||||||||
Pension curtailment gain | — | — | — | — | — | — | (15 | ) | (0.05 | ) | |||||||||||||||||||||||
Pension settlement gain | — | — | — | — | (32 | ) | (0.10 | ) | (1 | ) | — | ||||||||||||||||||||||
Other | 2 | 0.01 | 1 | — | 4 | 0.01 | 3 | 0.01 | |||||||||||||||||||||||||
Adjustment for taxes (a) | (17 | ) | (0.05 | ) | (10 | ) | (0.03 | ) | (32 | ) | (0.10 | ) | (27 | ) | (0.08 | ) | |||||||||||||||||
Non-GAAP Net income | $ | 187 | $ | 0.58 | $ | 145 | $ | 0.44 | $ | 359 | $ | 1.10 | $ | 298 | $ | 0.90 | |||||||||||||||||
(a) The adjustment for taxes excludes tax benefits that management believes are not directly related to on-going operations and which are either isolated or cannot be expected to occur again with any regularity or predictability. For the three and six months ended April 30, 2017, management uses a non-GAAP effective tax rate of 19.0%. In the same periods last year, management used a non-GAAP effective tax rate of 20.0%.
We provide non-GAAP net income and non-GAAP net income per share amounts in order to provide meaningful supplemental information regarding our operational performance and our prospects for the future. These supplemental measures exclude, among other things, charges related to amortization of intangibles, business exit and divestiture costs, transformational initiatives, acquisition and integration costs, pension curtailment gain and pension settlement gain.
Business exit and divestiture costs include costs associated with the exit of the NMR business and the divestiture of the XRD business.
Transformational initiatives include expenses associated with targeted cost reduction activities such as manufacturing transfers, small site consolidations, reorganizations, insourcing or outsourcing of activities. Such costs may include move and relocation costs, one-time termination benefits and other one-time reorganization costs.
Acquisition and Integration costs include all incremental expenses incurred to effect a business combination. Such acquisition costs may include advisory, legal, accounting, valuation, and other professional or consulting fees. Such integration costs may include expenses directly related to integration of business and facility operations, the transfer of assets and intellectual property, information technology systems and infrastructure and other employee-related costs.
Pension curtailment gain resulted from certain retirement plans benefit reductions.
Pension settlement gain resulted from transfer of the substitutional portion of our Japanese pension plan to the government.
Other includes certain legal costs and settlements in addition to other miscellaneous adjustments.
Our management uses non-GAAP measures to evaluate the performance of our core businesses, to estimate future core performance and to compensate employees. Since management finds this measure to be useful, we believe that our investors benefit from seeing our results “through the eyes” of management in addition to seeing our GAAP results. This information facilitates our management’s internal comparisons to our historical operating results as well as to the operating results of our competitors.
Our management recognizes that items such as amortization of intangibles can have a material impact on our cash flows and/or our net income. Our GAAP financial statements including our statement of cash flows portray those effects. Although we believe it is useful for investors to see core performance free of special items, investors should understand that the excluded items are actual expenses that may impact the cash available to us for other uses. To gain a complete picture of all effects on the company’s profit and loss from any and all events, management does (and investors should) rely upon the GAAP income statement. The non-GAAP numbers focus instead upon the core business of the company, which is only a subset, albeit a critical one, of the company’s performance.
Readers are reminded that non-GAAP numbers are merely a supplement to, and not a replacement for, GAAP financial measures. They should be read in conjunction with the GAAP financial measures. It should be noted as well that our non-GAAP information may be different from the non-GAAP information provided by other companies.
The preliminary non-GAAP net income and diluted EPS reconciliation is estimated based on our current information.
6
AGILENT TECHNOLOGIES, INC.
SEGMENT INFORMATION
(In millions, except where noted)
(Unaudited)
PRELIMINARY
Life Sciences and Applied Markets Group
Q2'17 | Q2'16 | |||||||
Revenues | $ | 523 | $ | 495 | ||||
Gross Margin, % | 59.9 | % | 58.5 | % | ||||
Income from Operations | $ | 110 | $ | 94 | ||||
Operating margin, % | 21.1 | % | 19.0 | % | ||||
Diagnostics and Genomics Group
Q2'17 | Q2'16 | |||||||
Revenues | $ | 201 | $ | 178 | ||||
Gross Margin, % | 57.6 | % | 54.1 | % | ||||
Income from Operations | $ | 49 | $ | 27 | ||||
Operating margin, % | 24.2 | % | 15.0 | % | ||||
Agilent CrossLab Group
Q2'17 | Q2'16 | |||||||
Revenues | $ | 378 | $ | 346 | ||||
Gross Margin, % | 49.7 | % | 49.3 | % | ||||
Income from Operations | $ | 82 | $ | 74 | ||||
Operating margin, % | 21.6 | % | 21.5 | % | ||||
Income from operations reflect the results of our reportable segments under Agilent's management reporting system which are not necessarily in conformity with GAAP financial measures. Income from operations of our reporting segments exclude, among other things, charges related to amortization of intangibles, business exit and divestiture costs, transformational initiatives, acquisition and integration costs, pension curtailment gain and pension settlement gain.
Readers are reminded that non-GAAP numbers are merely a supplement to, and not a replacement for, GAAP financial measures. They should be read in conjunction with the GAAP financial measures. It should be noted as well that our non-GAAP information may be different from the non-GAAP information provided by other companies.
The preliminary segment information is estimated based on our current information.
7
AGILENT TECHNOLOGIES, INC.
RECONCILIATION OF REVENUE BY SEGMENT EXCLUDING THE NMR BUSINESS,
ACQUISITIONS, DIVESTITURES AND THE IMPACT OF CURRENCY ADJUSTMENTS (CORE)
(In millions)
(Unaudited)
PRELIMINARY
Year-over-Year | |||||||||||||||||||
GAAP | |||||||||||||||||||
GAAP Revenue by Segment | Q2'17 | Q2'16 | Year-over-Year % change | ||||||||||||||||
Life Sciences and Applied Markets Group | $ | 523 | $ | 495 | 6% | ||||||||||||||
Diagnostics and Genomics Group | 201 | 178 | 13% | ||||||||||||||||
Agilent CrossLab Group | 378 | 346 | 9% | ||||||||||||||||
Agilent | $ | 1,102 | $ | 1,019 | |||||||||||||||
Non-GAAP | Currency Adjustments | Currency-Adjusted (a) | |||||||||||||||||
Non-GAAP Revenue by Segment | Q2'17 | Q2'16 | Year-over-Year % change | Q2'17 | Q2'17 | Q2'16 | Year-over-Year % change | ||||||||||||
Life Sciences and Applied Markets Group excluding NMR | $ | 523 | $ | 494 | 6% | $ | (3 | ) | $ | 526 | $ | 494 | 6% | ||||||
Diagnostics and Genomics Group excluding acquisition | 198 | 178 | 12% | (2 | ) | 200 | 178 | 13% | |||||||||||
Agilent CrossLab Group excluding acquisition | 376 | 346 | 9% | (4 | ) | 380 | 346 | 10% | |||||||||||
Agilent Revenue (Core) | $ | 1,097 | $ | 1,018 | $ | (9 | ) | $ | 1,106 | $ | 1,018 | 9% | |||||||
.
(a) We compare the year-over-year change in revenue excluding the effect of the NMR business, recent acquisitions and divestitures and foreign currency rate fluctuations to assess the performance of our underlying business. To determine the impact of currency fluctuations, current period results for entities reporting in currencies other than United States dollars are converted into United States dollars at the actual exchange rate in effect during the respective prior periods.
The preliminary reconciliation of GAAP revenue adjusted for the NMR business, recent acquisitions and divestitures and impact of currency is estimated based on our current information.
8